1. Home
  2. IMUX vs ANIX Comparison

IMUX vs ANIX Comparison

Compare IMUX & ANIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IMUX
  • ANIX
  • Stock Information
  • Founded
  • IMUX 2016
  • ANIX 1982
  • Country
  • IMUX United States
  • ANIX United States
  • Employees
  • IMUX N/A
  • ANIX N/A
  • Industry
  • IMUX Biotechnology: Pharmaceutical Preparations
  • ANIX Biotechnology: Pharmaceutical Preparations
  • Sector
  • IMUX Health Care
  • ANIX Health Care
  • Exchange
  • IMUX Nasdaq
  • ANIX Nasdaq
  • Market Cap
  • IMUX 86.3M
  • ANIX 82.7M
  • IPO Year
  • IMUX N/A
  • ANIX 1987
  • Fundamental
  • Price
  • IMUX $1.00
  • ANIX $3.14
  • Analyst Decision
  • IMUX Strong Buy
  • ANIX Strong Buy
  • Analyst Count
  • IMUX 6
  • ANIX 2
  • Target Price
  • IMUX $12.67
  • ANIX $8.50
  • AVG Volume (30 Days)
  • IMUX 923.9K
  • ANIX 128.9K
  • Earning Date
  • IMUX 02-24-2025
  • ANIX 03-11-2025
  • Dividend Yield
  • IMUX N/A
  • ANIX N/A
  • EPS Growth
  • IMUX N/A
  • ANIX N/A
  • EPS
  • IMUX N/A
  • ANIX N/A
  • Revenue
  • IMUX N/A
  • ANIX N/A
  • Revenue This Year
  • IMUX N/A
  • ANIX N/A
  • Revenue Next Year
  • IMUX N/A
  • ANIX N/A
  • P/E Ratio
  • IMUX N/A
  • ANIX N/A
  • Revenue Growth
  • IMUX N/A
  • ANIX N/A
  • 52 Week Low
  • IMUX $0.92
  • ANIX $2.07
  • 52 Week High
  • IMUX $2.11
  • ANIX $4.20
  • Technical
  • Relative Strength Index (RSI)
  • IMUX 50.39
  • ANIX 60.67
  • Support Level
  • IMUX $0.92
  • ANIX $2.87
  • Resistance Level
  • IMUX $0.97
  • ANIX $3.22
  • Average True Range (ATR)
  • IMUX 0.06
  • ANIX 0.18
  • MACD
  • IMUX 0.01
  • ANIX 0.02
  • Stochastic Oscillator
  • IMUX 66.61
  • ANIX 81.67

About IMUX Immunic Inc.

Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.

About ANIX Anixa Biosciences Inc.

Anixa Biosciences Inc, a cancer-focused biotechnology company, developing vaccines and therapies that are focused on critical unmet needs in oncology. The company is developing both diagnostics and therapeutics to detect cancer early, which is curable, and to treat those afflicted once diagnosed. Its segment includes CAR-T Therapeutics; Cancer Vaccines; Anti-Viral Therapeutics and others.

Share on Social Networks: